title: [Human papillomavirus vaccine register].
abstract: BACKGROUND
  We carried out an active surveillance of common adverse events occurring among women (9 to 26 years old) receiving human papillomavirus vaccine (Gardasil® and Cervarix®) in 9 Italian Regions.
  
  
  METHODS
  Common adverse events occurring in the two weeks following each dose administration were collected using a structured diary.
  
  
  RESULTS
  From August 2008 to September 2011, 12,066 immunised women (9,084 receiving Cervarix® and 2,982 Gardasil®) were included in the surveillance for a total of 29,494 administered doses. 53% of women concluded the vaccination cycle (74% with Gardasil® and 47% with Cervarix®). 61% of women experienced an adverse event after the administration of the first dose. The high proportion of adverse events reported is mainly due to the design of the study, since women were requested to report all events occurring after the vaccination; however the majority of events were mild and transient.
  
  
  CONCLUSIONS
  As for all vaccines, and in particular for newly marketed ones, the surveillance of adverse events represents an essential step in the evaluation of a vaccination programme.
authors.affiliation: Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Roma. stefania.spila@iss.it
authors.forename: Stefania
authors.initials: S
authors.lastname: Spila-Alegiani
authors.forename: Roberto
authors.initials: R
authors.lastname: Da Cas
authors.forename: Cristina
authors.initials: C
authors.lastname: Giambi
authors.forename: Roberto
authors.initials: R
authors.lastname: Raschetti
authors.forename: Stefania
authors.initials: S
authors.lastname: Salmaso
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000009:adverse effects; D012042:Registries; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines